TsRNA-SecTCA-L35 molecule and application of tsRNA-SecTCA-L35 molecule as colorectal cancer diagnosis biomarker and treatment target

By using tsRNA-SecTCA-L35 molecules as diagnostic biomarkers and therapeutic targets, combined with qRT-PCR detection and drug composition delivery, the problems of limited efficacy and large side effects in the treatment of colorectal cancer have been solved, enabling early diagnosis and effective treatment, and providing precise molecular targets and treatment strategies.

CN121801912AActive Publication Date: 2026-04-07GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)
6 Cites 0 Cited by

Patent Information

Application Number
CN202610051084.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-15
Publication Date
2026-04-07
Estimated Expiration
2046-01-15

AI Technical Summary

Technical Problem

Current treatments for colorectal cancer have limited efficacy, significant side effects, and insufficient targeting. They lack effective molecular targets and diagnostic biomarkers, resulting in poor treatment outcomes and making it difficult to achieve precision medicine.

Method used

Using tsRNA-SecTCA-L35 as a diagnostic biomarker, its expression level was detected by qRT-PCR. A diagnostic kit was developed, and oligonucleotide analogs were designed to upregulate its expression. The resulting drug composition was then used in combination with chemotherapy, targeted therapy, or immunotherapy for treatment.

Benefits of technology

It enables early, non-invasive diagnosis and effective treatment of colorectal cancer. Through the dual application of tsRNA-SecTCA-L35 molecules in diagnosis and treatment, it provides precise molecular targets and comprehensive solutions, significantly inhibiting cancer cell proliferation and promoting their death, which has important clinical application value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a tsRNA-SecTCA-L35 molecule and application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a colorectal cancer treatment target, and relates to the technical field of biological medicine. The invention provides application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a treatment target, in the diagnosis level, the molecule as a novel biomarker can be sensitively and specifically detected in samples such as plasma and tissue through qRT-PCR and other technologies, a brand new tool is provided for early discovery and non-invasive diagnosis of colorectal cancer, and the application of the tsRNA-SecTCA-L35 molecule as the colorectal cancer diagnosis biomarker and the treatment target is wide. In the aspect of treatment, by designing an analogue related to the molecular function and preparing the analogue into a pharmaceutical composition of a carrier such as lipidosome, the expression of the analogue in tumor cells can be effectively up-regulated, so that the proliferation of cancer cells is remarkably inhibited in vivo and in vitro, the death of the cancer cells is promoted, and the definite anti-tumor activity is shown; the important clinical application value is realized.
Need to check novelty before this filing date? Find Prior Art